Second Study

Second Study

HealthLinx has begun a second and larger 1150 patient multinational, multisite study that has been powered to detect differences in diagnostic efficiency (sensitivity and specificity) in symptomatic women.

The second study will further test the existing OvPlex™ panel of five biomarkers as well as two novel biomarkers being investigated by HealthLinx, AGR2 and HTX010. Based on preliminary data the company is expecting the diagnostic performance of the assay to increase from its current 94% to 97% or greater. 

Stage one of the second study which involves the testing of 450 samples, was launched on 15 July 2010 by Victorian Government Minister for Innovation, Industry and Regional Development, the Honourable Gavin Jennings. Results from this first stage of the study are expected in the third quarter of 2010.

The second stage of the study will commence when the remaining 700 samples are collected by our collaborating clinicians in Australia, the United Kingdom and Singapore. Planning and implementation of the trial design is currently underway at each of these clinical centres now that human ethics approvals have been finalised at each site

L to R: The Hon Gavin Jennings, Prof Greg Rice, Assoc Prof Lewis Perrin, 

Dr Dominic Autelitano, Nick Gatsios

L to R: The Hon Gavin Jennings, Prof Greg Rice, Assoc Prof Lewis Perrin

The Hon Gavin Jennings and Nick Gatsios

Collaborators and Supporters

HealthLinx is proud to have the following entities as collaborators and supporters involved with the second study.